Our Event Co-Chairs
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Paul Inman
With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.
Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.
As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.
Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.
Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.
Megan Chacon
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Paul Inman
With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.
Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.
As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.
Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.
Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.
Megan Chacon
What Are We Bringing In October?
Unlike any other patent litigation events in the U.S, this industry-led event has been carefully curated alongside in-house counsels from innovator, generic, biologic and biosimilar organisations to determine latest patent litigation frontiers shaping the U.S. jurisdiction and further afield.
VIEW THE FULL PROGRAM
Highlights For This Year Include
- BPCIA Litigation Review: Discover the latest in Innovator vs Biosimilar litigation in the USA
- Enablement and Plausibility: Seek out the outcome of Amgen vs Sanofi and how it is shaping inhouse patent litigation strategy
- Obviousness Type Double Patenting: Enhance your patent extension strategy with an updated approach towards PTAs and PTEs
- Share your views at Patent Litigation Strategy 24 Roundtables: Trade Secret – ADC – Next-Gen Therapeutics: benchmark and share your views on the latest patent protection strategy.
- Skinny Label Case Law Review: Understand the Latest Strategies and Updates from Novartis and Recordati
With a full slate of main-stage keynotes, breakout sessions, networking and more across three jam-packed days, you and your team will gain the connections and insights you need across three key pillars.
Our 2024 Speakers
Atabak Royaee
Bart Newland
Beth Krewson
Catherine Drew
Chris Sharp
Dan McGrath
Dan is an experienced patent litigator who advises clients on a wide range of intellectual property issues. He has considerable experience in biopharmaceutical patent and supplementary protection certificate litigation and has represented clients in some of the most complex technical disputes tried in the English courts. Dan also has significant expertise in litigation before the Unified Patent Court and is currently instructed on several high-profile patent disputes. Dan sits on the BioIndustry Association's IP Advisory Committee and its SPC sub-committee.
In the UK, Dan has advised clients in actions in the High Court and Court of Appeal. Dan regularly manages multi-jurisdictional disputes, co-ordinating and working with litigation teams globally. He has been involved in hearings at the Unified Patent Court, European Patent Office, District Court in The Hague and in North America.
With a keen interest in scientific innovation, Dan is readily able to master highly technical issues and has a strong grasp of the technical and commercial landscape in which his clients operate
David Shofi
Eric Choi
Fiona Legere, Partner, Blakes
Gwilym J.O. Attwell
Geoffrey Biegler
Hon. Mitchell S. Goldberg
Hon. Paul R. Michel (Ret.)
Jim Burns, Senior Director
John Cox
With deep knowledge of issues facing the life sciences industry, John Cox counsels clients regarding their worldwide intellectual property rights and represents their patent interests when litigation arises, particularly regarding pharmaceutical, chemical, and biotechnology matters. John takes his role in protecting these important assets of life science innovators very seriously while approaching each matter with enthusiasm.
Through his ability to communicate effectively and succinctly, John advises on, develops, and carries out global IP strategies for the benefit of innovative companies, his clients, who are focused on developing core assets that save and improve the lives of patients. John enjoys leveraging his unique ability to put together targeted and enduring teams for each matter – paying close attention to each person’s strengths and skillsets and how they fit with one another, alongside his highly specialized experience and thoughtful and responsive nature.
John is intimately familiar with the pharmaceutical industry, having dealt with patent and IP subject matter ranging from brain chemistry, the gastrointestinal system, drug delivery systems and treatments of rare diseases and cancer to medical diagnostic methods, the generation of biofuel using bacteria, and processes for manufacturing chemicals and pharmaceutical products. He also has almost two decades of experience in Abbreviated New Drug Application (ANDA) cases, including pre-litigation investigations.
John offers guidance from the first step of a matter through to resolution, including all aspects of litigation. He has extensive experience related to discovery and motion practice, as well as in developing offensive and defensive strategies. He is well versed in dealing with complex subject matter and technical witnesses, such as inventors and experts.
John adeptly helps clients navigate the crossroads of foreign business practices and the complexities of U.S. patent practice, having worked with foreign pharmaceutical, chemical, and biotechnology companies throughout his career.
Joshua Kresh
John Norman
Kamleh Nicola
Kamleh Nicola is a partner at Marks & Clerk and Co-Head of the firm’s Litigation practice in Canada. Her intellectual property litigation practice centers around patent, trademark, and copyright disputes. Though her client base is broad in scope, she specializes in Health and Life Sciences, working with domestic and multinational pharmaceutical, biopharma, and MedTech organizations. Kamleh is particularly knowledgeable on matters involving Canada’s patent linkage regimes, health regulatory and related compliance, and trade secrets.
Kevin Yurkerwich
Kristin Cooklin
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Matt Murphy
Martina Tyreus Hufnal
Paul Inman
With more than 25 years' experience of litigating intellectual property (IP) disputes both within the UK and internationally, Paul Inman works with companies ranging from small start-ups to major multi-national corporations. He specialises in the life sciences sector, which includes acting on high-profile pharmaceutical patent infringement cases in the UK Patents Court.
Paul provides life science businesses with commercial advice from an international outlook. His specialist experience ideally places him to provide this expertise and client care, with the ultimate aim of delivering well-rounded advice and guidance to ensure the best possible outcome.
As well as litigating in the English courts, he has co-ordinated and advised on IP and regulatory litigation matters across the globe; from all over Europe and the US, to as far afield as Asia, South Africa, Australia and New Zealand.
Successfully guiding clients through the maze of litigation is where Paul's strength lies, having now been involved over 25 years of litigation in cases leading to more than 40 reported judgments. These range from the tribunals of the UK Patent Office up to the House of Lords, European Patent Office and European Court of Justice.
Paul also has a degree in Molecular Biology and Biochemistry and during his professional career has established an outstanding reputation in the market. He is distinguished in the 2023 edition of IAM Patent 1000: The World's Leading Patent Professionals, ranked individually for both IP law and life sciences law in the peer review publication 'Best Lawyers® in the UK' and recognised in several categories within Chambers & Partners UK 2023.
Petra Scamborova
Raymond Parker III
Robert Oakes
Robin Ellis
Venkata S S K Garimella
Sophie Wang
Stephanie Monaco
Victoria Reines
Stan Fisher
Stan Fisher is a first-chair trial lawyer and counselor who focuses his practice primarily on issues that affect technology companies. Stan has tried numerous cases involving patent, FDA, and antitrust issues, as well as matters involving contracts, licensing, and business torts.
Stan has been consistently ranked as an “IP Star” by Managing Intellectual Property (2021-2024); and LMG Life Sciences Guide recognized him as a “Leading Life Science Star” since 2021. In 2022, LMG Life Sciences identified Stan among the finalists for the “General Patent Litigator of the Year (DC Metro)” award, and in 2023, he was a recognized as a finalist for “Hatch-Waxman Litigator of the Year (Branded)." IAM Patent 1000 has highlighted Stan as a “Leading Patent Litigation Attorney” in its guide since 2020. The 2020 publication noted Stan has “broad horizons as a trial lawyer and litigates with confidence and poise in diverse technical fields, across all areas of intellectual property and in regulatory, antitrust and contract disputes” and the 2022 edition emphasizes Stan’s standing as a “leading trial lawyer.” Both in September 2022 and May 2021, The American Lawyer recognized Stan as a “Litigator of the Week Runner Up” for successfully representing Merck in a major trial victory and IPR proceedings, respectively, concerning patents covering the blockbuster sitagliptin products: Januvia, Janumet, and Janumet XR.
In addition to Stan’s patent practice, he serves as Co-Chair of the firm’s Food and Drug Administration practice group. In this space, he focuses specifically on the intersection of FDA law, patent law, and antitrust law, advises on issues with the Orange Book, regulatory exclusivities, and other issues that are adjunct to pharmaceutical and biotech patent litigation. Stan’s experience litigating matters involving the FDA has been highlighted by IAM Patent 1000 with the publication describing Stan as a “top” FDA lawyer. The 2021 edition highlighted Stan's "vast biopharmaceutical experience” and explained that he “makes full use of his finely honed advocacy skills and intuitive understanding of Food and Drug Administration regulatory requirements and antitrust law." He also has an active practice litigating trade secrets, trademarks, and copyrights.
Stan serves as Professorial Lecturer in Law at The George Washington University Law School, where he teaches Chemical & Biotech Patent Law, a course Stan recently re-designed to focus on patent, regulatory, and antitrust issues arising in Hatch-Waxman, BPCIA, and other pharmaceutical and biotechnology patent matters.
Stan received his B.S. in Molecular Biophysics & Biochemistry from Yale College in 1997 and his J.D. from The George Washington University Law School in 2004, where he graduated with Highest Honors and served as Editor-in-Chief of The George Washington Law Review. He joined Williams & Connolly in March 2006 after clerking for Judge Richard Linn at the U.S. Court of Appeals for the Federal Circuit. Stan is a current member of the firm's Budget Committee and former member of the Hiring Committee. Stan is a Past President of the Giles S. Rich American Inn of Court, the Intellectual Property Inn of Court in Washington, D.C. generally affiliated with the U.S. Court of Appeals for the Federal Circuit.
Jacqueline Bonilla
Kassie Helm
Marina Volin
Merri Moken
William Simmons
Bonnie Fletcher Price
Agenda
"The event provided an exceptionally strong palette of issues relevant for practitioners in the pharma/biotech patent litigation field. The panels were of high quality and I particularly appreciated the practical and transparent insights of industry speakers and UPC judges. The venue and logistics were also excellent, a really high quality conference overall." - Danubia Legal
Our conference programme features the latest insights from the industry’s top companies and key thoughts-leaders, tackling the most pertinent issues and trends in the industry.
With three stages of content, you’ll be able to tailor your perfect agenda to meet your specific business needs – allowing you & your team to gain the tangible intel you need to fast-track your product development over the next 12 months.
Portfolio Testimonials
I had two goals in attending the litigation conference, and both were accomplished. First, network:
in just two short days, I met a number of lawyers who I may call to one day for advice or just to chat.
Second, learn: the presentations and roundtables provided just the right depth for someone like me, a
US-trained lawyer, who wanted to learn more about ex-US IP law and litigation. I am grateful for having
the opportunity to speak at the conference, and I look forward to attending others to come.
It is always great to attend conferences wherein both in house and law firm speakers are there, in addition when we can get generic and innovators views
Great topics and high quality speakers. Not to forget about the great networking opportunities face to face. I truly enjoyed the event.
Good, relevant and practical topics, with good interaction between attendees and frank but respectful exchanges of views.
Package
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase in
— —
- Tuesday, May 21, 2024 to Friday, July 5, 2024Tier 2 - Law Firms$999Only 6 places available at this rate!
- Saturday, July 6, 2024 to Friday, August 9, 2024Tier 2 - Law Firms$1499Super Early Bird Rate - Save $600
- Saturday, August 10, 2024 to Thursday, September 5, 2024Tier 2 - Law Firms$1899Early Bird Rate - Save $200
- Friday, September 6, 2024 to Friday, October 4, 2024Tier 2 - Law Firms$1999Final Early Bird - Save $100
- Tuesday, May 21, 2024 to Friday, July 5, 2024Tier 3 - Service Providers$1499Save $1500
- Saturday, July 6, 2024 to Friday, August 9, 2024Tier 3 - Service Providers$1999Super Early Bird Rate - Save $1000
- Saturday, August 10, 2024 to Friday, September 13, 2024Tier 3 - Service Providers$2499Early Bird Rate - Save $500
- Saturday, September 14, 2024 to Friday, October 4, 2024Tier 3 - Service Providers$2799Final Early Bird - Save $300
- Saturday, October 5, 2024 to Wednesday, October 30, 2024Tier 3 - Service Providers$2,999Standard Price
Register Your Interest for 2024
Why this is The Must attend event for you?
- Network with in-house and private practice life science IP litigation experts within the USA and build long-lasting commercial relationships.
- Gain a competitive edge by discover the latest case law in the U.S. and Europe
- Expand your horizon by discovering the next frontier of patent litigation landscape: Novel Therapeutics, Trade Secret, AIDD and ADC.
From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick "YES!".
Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].
User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].
For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.
By clicking submit below, you consent to allow Kisaco Research to store and process the personal information submitted above to provide you the content requested.
Download the Full Program Below
Life Sciences Patent Advisory Board
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Mathilde Rauline
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Ewan Nettleton
Tessa M. Malamud-Cohen
Paki Banky
Corinna Sundermann
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Toni Santamaria
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
Dr. Leslie Fischer
Leslie Fischer is a Principal Patent Attorney at Sandoz, who focuses on global IP strategy for biosimilars. Before joining Sandoz, Leslie was a patent attorney at Novartis Pharmaceuticals, where she worked for over a decade developing global patent portfolios for biologicals. Before joining the Novartis group, Leslie was an associate at Fitzpatrick Cella (NY) (now Venable). Leslie holds a J.D. from Rutgers University and a Ph.D. in Biochemistry from Thomas Jefferson University. Her scientific work appears in JCB, JBC, and Osteoarthritis & Cartilage. She speaks frequently at patent-related events and is an adjunct professor at Seton Hall Law School.
Christof Bull
Mathilde Rauline
Mathilde is a European patent attorney, is qualified as a French patent attorney, and is admitted to the Paris bar.
She is head of Greater Europe patent litigation at Sanofi, after having been a patent litigator in private practice (mostly in the pharmaceutical field), and a patent attorney in the industry (Sanofi, Nestlé).
She has extensive experience in pharmaceutical and life-science patent litigation in France, at the EPO, in Europe, and in Eurasia.
Her expertise also comprises contractual matters, settlements, regulatory aspects, and the SPC regulation.
Lorenz Kallenbach
Lorenz Kallenbach is a senior corporate patent counsel in the healthcare division of Merck KGaA. He is responsible for defining and executing the IP strategy for innovator projects. Including the assessment of the IP landscape, coordination of worldwide patent litigation, and portfolio development.
Before joining Merck, Lorenz worked in private practice. He is qualified as a German and European patent attorney.
Lorenz studied biochemistry and received a Ph.D. in the field of epigenetics.
Stephan Kutik
Ewan Nettleton
Tessa M. Malamud-Cohen
Paki Banky
Corinna Sundermann
Frank Landolt
Frank Landolt is Chief Counsel, Intellectual Property and Legal at Confo Therapeutics, a privately held biopharmaceutical start-up based in Ghent, Belgium specializing in GPCR-targeted therapeutics.
After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.
Prior to joining Confo in 2018, Frank worked for fifteen years in Ablynx N.V. (now a wholly owned Sanofi company), where he was a member of the management team and headed an integrated IP and legal group of four lawyers and five patent professionals. At Ablynx, Frank was involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, Boehringer-Ingelheim, MSD, Merck-Serono, Novartis, Novo Nordisk, Sanofi and Wyeth.
From 2000 to 2004, Frank was director of IP and legal counsel at Devgen N.V. (now part of Syngenta), another Ghent-based biotechnology company, where he was involved in negotiating Devgen’s strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.
Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI and LES Benelux (where he is involved in the LES Licensing Course). He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector. Frank was named as one of Managing IP’s ‘Corporate IP stars’ for four years in a row (2015-2018).
Guido Pontremoli
Currently employed as global Head of the IP department-Patent at Chiesi Farmaceutici SpA, managing and coaching a team of experienced patent attorneys, patent searchers and administrators, working on the protection, enforcement, litigation and/or opposition of the Chiesi IP, aligned with business decisions.
Before joining Chiesi, I worked in IP groups of big pharma companies (GSK Vaccine, and Bracco Imaging) as senior patent attorney responsible for all the IP aspects concerning some key R&D projects. I also had experience as patent counsel in private practices, dealing with pharma, chemical and bio entities.
Graduated in chemistry from the Univ of Milan, with a PhD in medicinal chemistry and a post-doc experience in USA, I am qualified EPA and chartered Italian patent attorney.
Kristin Cooklin
Toni Santamaria
Toni has been leading the Intellectual Property team at Adalvo since 2021. He has more than 20 years of experience in different pharmaceutical companies where he has been involved in developing and implementing complex patent and data exclusivity litigation strategies for several generics and added value products, including leading parallel litigation cases in multiple European countries. He also has experience in patent and trademark prosecution.
Toni qualified as European Patent Attorney in 2010 and holds a PhD in Organic Chemistry.
Shohta Ueno
IN PARTNERSHIP WITH
Platinum Partners
Fish & Richardson
Website: https://www.fr.com/industries/life-sciences/
Fish & Richardson has represented pioneering life science innovators from our earliest days. We work closely with life sciences companies to help them achieve their strategic IP goals through acquisition, partnering, licensing, financing, and enforcement. We do this by bringing a unique holistic approach to our clients’ IP matters, fostered by the collaboration between our patent prosecution, litigation, and regulatory practices. We have helped our clients build valuable patent portfolios worth billions of dollars, score big victories at the Patent Trial and Appeal Board (PTAB), and win bet-the-company cases in court. When life sciences clients come to Fish to build an IP strategy, they know that we will leave no stone unturned when crafting creative and comprehensive solutions to maximize the value of their IP.
Gowling WLG
Website: https://gowlingwlg.com/
With more than 1,500 legal professionals in offices worldwide, Gowling WLG offers clients a comprehensive suite of sector-focused legal services. With an award winning global intellectual property practice, our full service firm stands out for its ability to provide support for the full life cycle of a smart idea.
Trade secret protection is an important part of this offering with services spanning multiple disciplines – from the development of trade secrets and data protection policies, to the drafting of NDAs and employment contracts, through to cybersecurity risk management and high stakes litigation.
Whether you are looking to identify and protect your trade secrets to avoid leakage, establishing the value of your intangible assets for merger or acquisition or pursuing a trade secret thief, we can help guide you through trade secrets law around the world and across a number of key sectors. Learn more
Marks & Clerk
Website: https://www.marks-clerk.com/
Marks & Clerk is an international law firm specialising in intellectual property (IP) law. With a vast network of over 650 professionals across the world, including a qualified team of experienced patent and trademark associates, the firm offers comprehensive technical expertise covering all aspects of intellectual property matters, such as patents, trademarks, designs and copyright. Its services encompass worldwide protection, portfolio management, strategic advice, commercial guidance, licensing, enforcement, clearance and searches, validity and infringement opinions, due diligence and litigation. Operating through a network of offices in Canada, Europe and Asia, Marks & Clerk consistently delivers high-quality, seamless and cost-effective services to clients both locally and globally.
Pinsent Masons
Website: https://www.pinsentmasons.com/
Pinsent Masons international Life Sciences practice is one of the best in Europe.
Their team, comprising more than 100 sector specialists, many of whom are leading individuals in their field with relevant scientific degrees (some to Ph.D.) and experience, drawn from industry, is dedicated to helping their clients continue to develop cutting-edge strategies that use the law as a business enabler to positively impact their bottom line.
The team acts for businesses globally on complex market shifting transactions; cutting edge R&D collaboration; partnering and licensing deals; the most high profile, business-critical patent and regulatory litigations; and hugely impactful anti-trust investigations and litigations.
Comprising some of the world’s leading life sciences experts, the team works with senior management and in-house legal teams to navigate complex regulatory environments, develop effective risk management strategies, and spot and convert opportunities.
Gold Partners
Axinn, Veltrop & Harkrider, LLP
Website: https://www.axinn.com/
Axinn combines the skills, experience and dedication of the world's largest firms with the focus, responsiveness, efficiency and attention to client needs of the best boutiques. The firm was established in the late 1990s by lawyers from premier Wall Street firms with a common vision: provide the highest level of service and strategic acumen in antitrust, intellectual property and high-stakes litigation. Axinn's lawyers have served as lead or co-lead counsel on nearly half a trillion dollars in transactions and, in the last 10 years alone, have handled more than 300 litigations.
Barnes And Thornbug LLP
Website: https://btlaw.com/
Intellectual Property
Barnes & Thornburg’s Intellectual Property Department, with more than 130 attorneys and professionals, is one of the largest intellectual property practice groups found in a full-service law firm. Our practice covers a broad spectrum of services, including strategic IP portfolio services, prosecuting and litigating patents, trademarks and copyrights, enforcement of patents and trademarks, and defense of IP enforcement actions.
Our IP practice advises and helps a diverse and multinational roster of clients. From electrical and mechanical engineering, to chemistry and microbiology, to computer technology and business methods – our attorneys’ background and experience in several technical disciplines positions us to meet a variety of sophisticated business and inventorship needs.
Life Sciences
Barnes & Thornburg provides a wide range of interdisciplinary legal services to organizations engaged in biotechnology, pharmaceuticals, medical and laboratory devices, health services and bioinformatics. Most of the lawyers in our biotech practice have educational and practical research experience pertinent to the biotechnology industry and many hold advanced degrees in organic chemistry, pharmacology, molecular biology, genetics, immunology and microbiology. We understand chemistry, biotech, pharmaceutical, and medical device technologies. In addition, our intellectual property practice includes professionals with advanced degrees in molecular biology, chemistry, organic chemistry, biochemistry, genetics, biology, pharmacology, immunology, microbiology, biotechnology, bioengineering, physics, mechanical engineering, electrical engineering, industrial engineering, and civil engineering.
Our team represents a wide array of clients in this industry – from startups to Fortune 500 companies. Some of our representative clients include 3M Company, DePuy Orthopaedics, Inc., Eli Lilly and Company, Johnson & Johnson, H.D. Smith Wholesale Drug Co., Hillenbrand, \
Blakes
Website: https://www.blakes.com/
Blakes builds long-term relationships with decision-makers in Canada and abroad, delivering top-tier legal advice and service in all major Canadian business centres, as well as New York and London.
Brown Rudnick LLP
Website: https://brownrudnick.com/
Brown Rudnick is an international law firm that serves clients around the world from offices in key financial centers in the United States and the United Kingdom. We combine ingenuity with experience to achieve great outcomes for our clients in high-stakes litigation and complex business transactions. We deliver partner-driven service; we incentivize our lawyers to collaborate in the client’s best interest; and we put excellence before scale, focusing on industry-driven, client-facing practices where we are recognized leaders.
Solutions Partner
RWS
Website: https://www.rws.com/intellectual-property-services/
RWS is the world’s leading provider of technology-enabled language, content management, and intellectual property services. With over 60 years of experience in the IP arena RWS expertise in patent translations, foreign filing and IP research services is unrivalled.
Clients trust RWS to deliver high-quality translations in a format ready for filing, in compliance with national filing formalities and maintaining exactly the same protective scope as the original.
RWS also helps clients simplify and streamline their internal processes, by providing flexible, cost-effective foreign filing and renewals services dramatically reducing the administrative burden associated with EP validations, PCT national phase entries and direct filings.
When it comes to research, RWS offers the most robust intellectual property (IP) researcher services and tools available. From our market leading patent research database, PatBase, to the world’s most comprehensive set of IP search offerings from desk based analysts to crowdsearch.
RWS clients include many of the world's largest filers including 19 of the top 20 applicants at the World Intellectual Property Organization and 16 of the top 20 applicants at the European Patent Office.
Founded in 1958, RWS is headquartered in the UK and publicly listed on AIM, the London Stock Exchange regulated market (RWS.L).
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase in
— —
- Tuesday, May 21, 2024 to Friday, July 5, 2024Tier 2 - Law Firms$999Only 6 places available at this rate!
- Saturday, July 6, 2024 to Friday, August 9, 2024Tier 2 - Law Firms$1499Super Early Bird Rate - Save $600
- Saturday, August 10, 2024 to Thursday, September 5, 2024Tier 2 - Law Firms$1899Early Bird Rate - Save $200
- Friday, September 6, 2024 to Friday, October 4, 2024Tier 2 - Law Firms$1999Final Early Bird - Save $100
- Tuesday, May 21, 2024 to Friday, July 5, 2024Tier 3 - Service Providers$1499Save $1500
- Saturday, July 6, 2024 to Friday, August 9, 2024Tier 3 - Service Providers$1999Super Early Bird Rate - Save $1000
- Saturday, August 10, 2024 to Friday, September 13, 2024Tier 3 - Service Providers$2499Early Bird Rate - Save $500
- Saturday, September 14, 2024 to Friday, October 4, 2024Tier 3 - Service Providers$2799Final Early Bird - Save $300
- Saturday, October 5, 2024 to Wednesday, October 30, 2024Tier 3 - Service Providers$2,999Standard Price
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.
We'd love to hear from you.
Contact us at +44 (0)20 3696 2920 and email [email protected], or let us know what subject area you're interested in below.